GLP-1 Telehealth Provider Comparison: Which Platforms Actually Monitor You Properly?

Not all GLP-1 telehealth providers are equal. Some order comprehensive labs, assign specialist physicians, and track your progress monthly. Others send a prescription within 24 hours of a questionnaire — and never check in again. This GLP-1 telehealth provider comparison covers the platforms patients actually use in 2026: Hims, Ro, Calibrate, Mochi Health, Henry Meds, and Meto. The verdict is clear. If you want a prescription fast, several platforms deliver. If you want to be monitored like a real patient, the list gets much shorter.

Why Monitoring Is the Only Metric That Matters in a GLP-1 Telehealth Provider Comparison

GLP-1 receptor agonists — semaglutide and tirzepatide — are powerful metabolic drugs. The STEP-1 trial demonstrated mean weight loss of 14.9% with weekly semaglutide.[1] The SURMOUNT-1 trial showed 20.9% with tirzepatide.[2] The SELECT cardiovascular outcomes trial revealed a 20% reduction in major adverse cardiovascular events among non-diabetic patients with obesity.[3]

These are not supplements. They are drugs with real contraindications, organ-level effects, and interaction risks. They require:

• Kidney function monitoring (GLP-1s require dose adjustment in renal impairment)
• Thyroid screening (personal or family history of medullary thyroid carcinoma is an absolute contraindication)
• HbA1c and blood glucose tracking
• Pancreatic enzyme awareness in at-risk patients
• Lipid panel follow-up
• Blood pressure monitoring

The American Diabetes Association Standards of Medical Care recommend HbA1c, renal function, and lipid panels as part of baseline metabolic assessment before initiating GLP-1 therapy.[4] The American Association of Clinical Endocrinology similarly recommends comprehensive metabolic evaluation — including thyroid assessment — prior to weight loss pharmacotherapy.[5]

Many telehealth platforms do not meet these standards. That is the real story behind every GLP-1 telehealth comparison.

If you want to understand the full mechanism and clinical profile of these drugs before comparing providers, Meto's clinical breakdown of how semaglutide and tirzepatide work is a useful starting point.

What Proper GLP-1 Monitoring Actually Looks Like

Before you compare any platform, know the clinical standard they should be held to.

Baseline Labs Before You Start

These are the biomarkers that should be tested before any GLP-1 prescription is written:

If a platform skips this step, it cannot know whether you have undiagnosed kidney disease, an elevated A1c that changes your clinical category, or a thyroid condition that makes GLP-1s contraindicated.

Follow-Up Cadence That Matches Clinical Guidelines

The ADA recommends HbA1c monitoring every three months until targets are met, then every six months.[4] The Obesity Medicine Association's position statement on telehealth prescribing is explicit: remote or asynchronous prescribing must not lower the clinical standard of care.[6]

Minimum acceptable follow-up for a monitored GLP-1 program:

1. Labs repeated at 3 months post-initiation
2. Clinical check-in (video or async) at weeks 4, 8, 12
3. Dose adjustments based on response and tolerability
4. Annual metabolic panel and cardiovascular risk reassessment
5. Documented titration protocol — not just escalation on demand

Prescriber Qualifications

There is a meaningful difference between a general practitioner and a board-certified obesity medicine specialist or endocrinologist. GLP-1s interact with insulin secretion, gut motility, renal clearance, and thyroid physiology. Specialists understand these interactions. Volume-focused platforms often do not disclose prescriber credentials at all.

GLP-1 Telehealth Provider Comparison: The Six Platforms Reviewed

Here is how the major platforms stack up against the clinical monitoring standard.

Hims

Hims became the most recognised name in GLP-1 telehealth through aggressive marketing and low-friction onboarding. In March 2026, Hims settled with Novo Nordisk and exited compounded semaglutide for new patients, pivoting to branded Wegovy and Zepbound.[7] The platform now offers injectable Wegovy at $299/month, oral Wegovy at $249/month, and Zepbound at $399/month, with commercial insurance bringing costs to $0–$25/month for eligible patients.

What they do: Questionnaire-based intake, async-only consultations, no live video visits, no required pre-treatment lab work, no specialist assignment.

What they don't do: Order labs before prescribing. Hims' intake process does not require — or routinely request — bloodwork. The FDA issued 30 warning letters in March 2026 to telehealth companies for misleading claims about compounded GLP-1 products, and Hims was among those that discontinued compounded promotion.[7]

Clinical verdict: Fast access to branded GLP-1 medication with insurance support. No clinical monitoring infrastructure. Appropriate only for patients with very recent normal labs from another provider who want a streamlined prescription experience.

Ro Body Program

Ro takes a step up from Hims. Their Body Program pairs GLP-1 prescribing with coaching and metabolic support. Ro accepts insurance for brand-name medications and has an insurance navigation concierge that handles prior authorisation — a genuine differentiator for patients with Wegovy or Zepbound coverage.

What they do: Async consultations for compounded medications; video options for branded. Labs are conditionally required, triggered by intake questionnaire responses, not universally mandated. Their Body Program includes some metabolic lab testing.

What they don't do: Require labs for all patients. Monitoring cadence is inconsistent. Prescribers are not specialists.

Pricing: $149–$499/month depending on medication and insurance status.

Clinical verdict: More infrastructure than Hims. Insurance navigation is genuinely useful. Lab monitoring is conditional, not systematic. Not a specialist-supervised program.

Calibrate

Calibrate operates differently from every other platform on this list. Their product is a structured, one-year metabolic reset program combining GLP-1 medication with physician oversight, quarterly lab work, health coaching, and curriculum-based lifestyle intervention. They accept insurance for brand-name medications.

What they do: Require baseline metabolic labs before prescribing. Deliver quarterly lab monitoring. Pair patients with physicians (not obesity medicine specialists specifically, but medically qualified prescribers). Provide structured coaching and behavioural support.

What they don't do: Deploy board-certified obesity medicine specialists universally. Pricing at full cost is significant — the program is primarily viable through insurance.

Clinical verdict: The most structured non-specialist program available at scale. Lab monitoring is built in, not conditional. The year-long program structure incentivises genuine clinical follow-up. Best for patients who want a supported, program-style approach with insurance coverage.

Mochi Health

Mochi Health is the specialist platform. They exclusively employ board-certified obesity medicine physicians — a meaningful clinical distinction. Obesity medicine certification requires dedicated training in adiposity, metabolic dysfunction, and pharmacological management that generalists do not receive.

What they do: Assign board-certified obesity medicine specialists. Require baseline labs before prescribing. Offer both brand-name and compounded options. Accept insurance. Provide clinical consultations with qualified prescribers.

What they don't do: Serve patients whose conditions extend beyond weight management to include PCOS, insulin resistance, thyroid pathology, or hormonal disorders. They are obesity-focused, not metabolic medicine-focused.

Pricing: $149+/month, variable with insurance.

Clinical verdict: Best specialist-supervised platform for straightforward obesity management. Lab requirements are enforced. Monitoring is more rigorous than most. Not designed for complex metabolic or hormonal presentations.

Henry Meds

Henry Meds built its business around low-cost compounded semaglutide at a flat $149/month. The FDA's 503B compounding enforcement actions, which escalated through 2025, have placed significant pressure on this model. Compounded semaglutide supply has declined and regulatory risk is ongoing.[8]

What they do: Provide flat-rate, low-friction access to compounded GLP-1s. Month-to-month pricing with no dose-dependent increases.

What they don't do: Require pre-treatment labs. Henry Meds' intake is questionnaire-only. No monitoring cadence. No specialist access.

Clinical verdict: The most affordable option, with the least clinical infrastructure. The compounding supply chain is under sustained regulatory pressure. Not appropriate for patients with complex metabolic histories or any unscreened risk factors.

For more on the regulatory landscape affecting compounded GLP-1 access, Meto's breakdown of the 2026 FDA compounded peptide crackdown explains what has changed and what it means for patients.

Meto

Meto is a metabolic and hormonal health platform — not a weight loss app with a GLP-1 add-on. The clinical model reflects that distinction. Meto treats obesity, insulin resistance, PCOS, perimenopause, thyroid disorders, and metabolic syndrome as interconnected conditions rather than separate silos. That matters for GLP-1 prescribing, because most patients presenting with weight concerns also have underlying hormonal or metabolic drivers that other platforms never assess.

What they do:

• Require comprehensive pre-treatment labs before prescribing
• Accept most major insurance plans (average patient copay: $0–$50)
• Provide access to metabolic specialists — not generalists
• Build ongoing monitoring into the treatment program
• Track biometric changes, lab results, and symptoms with continuous clinical oversight
• Offer a purpose-built metabolic lab panel that covers every relevant biomarker in a single draw

What they don't do: Rush prescriptions without clinical basis. Treat weight loss as the only outcome.

Pricing: Most visits $0–$50 with insurance. Transparent self-pay rates for the uninsured.

Clinical verdict: The only platform that combines insurance coverage, specialist access, required labs, and ongoing monitoring within a metabolic medicine framework. The right clinical model for patients with complex metabolic presentations — or anyone who wants to be monitored like a real patient, not just prescribed.

The GLP-1 Telehealth Provider Comparison: Monitoring Scorecard

The Real Cost of Skipping Monitoring

The platform with the lowest upfront price is not always the cheapest option. Consider what inadequate monitoring can miss:

Undiagnosed kidney disease. GLP-1s require dose adjustment or avoidance when eGFR falls below certain thresholds. Starting without renal labs in a 55-year-old with hypertension is a clinical oversight with real consequences.

Thyroid pathology. Medullary thyroid carcinoma (MTC) and Multiple Endocrine Neoplasia type 2 (MEN 2) are absolute contraindications to GLP-1 therapy.[9] A TSH and thyroid history review are minimum requirements. Many questionnaire-only platforms do not catch this.

Undiagnosed diabetes. A patient with an HbA1c of 7.8% is diabetic, not simply overweight. Their prescribing protocol, monitoring targets, and likely co-prescriptions are different. Skipping the A1c means treating a diabetic as an obesity patient — with potential complications.

Medication interactions. GLP-1s affect gastric emptying, which changes the absorption of oral medications. Patients on thyroid hormone replacement, oral contraceptives, or certain antibiotics may see altered drug levels. A prescriber who reviewed only a questionnaire will not catch this.

Pancreatitis risk. Active pancreatitis or a history of pancreatitis is a contraindication. Without a metabolic panel and clinical history review, this is routinely missed by volume-focused platforms.

For a full exploration of what GLP-1s actually do to your metabolic system — beyond the scale — Meto's article on the 8 metabolic effects your doctor should tell you about covers the cardiovascular, hepatic, renal, and neurological dimensions of treatment.

Semaglutide Online Prescription Safety: What to Verify Before You Enroll

If you are evaluating a platform for a semaglutide online prescription, run through this checklist before you commit:

1. Do they require labs before prescribing? If no, ask why. The answer matters.
2. Who writes your prescription? Confirm the prescriber's credentials. Are they a licensed physician, an NP, or a PA? Are they trained in obesity or metabolic medicine?
3. Is the medication compounded or FDA-approved? Understand the regulatory distinction. Compounded semaglutide is not an FDA-approved finished product. Read Meto's guide on research peptides vs pharmaceutical-grade quality standards for context on what manufacturing standards mean for your safety.
4. What happens at month three? Ask about the follow-up protocol explicitly. If there is no structured monitoring cadence, you are on your own.
5. Can you access a specialist if complications arise? Know the escalation pathway before you start.
6. Does your insurance cover it — and is the platform set up to use it? Several platforms accept insurance in theory but have no infrastructure to navigate prior authorisation. Confirm before enrolling.

The GLP-1 Peptide FAQ on Meto's blog answers 15 of the most common pre-treatment questions in clinical detail — a useful resource for anyone preparing for a prescriber conversation.

The GLP-1 Patient Who Needs More Than a Prescription

GLP-1 therapy is rarely the whole story. The majority of patients seeking GLP-1s present with one or more of the following:

• Insulin resistance or prediabetes
• PCOS or hormonal dysregulation
• Thyroid dysfunction
• Perimenopause-related metabolic changes
• Metabolic syndrome with multiple cardiovascular risk factors

A platform that treats weight as the only relevant variable will miss most of these. Semaglutide and tirzepatide address GLP-1 receptor signalling — but if insulin resistance is driven by cortisol dysregulation, thyroid pathology, or androgen excess (common in PCOS), a prescription alone will not resolve it.

Meto's clinical model is built around this reality. The Insulin Resistance and Prediabetes Reset, Hormonal and PCOS Management, and Perimenopause and Menopause Support programs all operate alongside the Prescription Weight Loss Program — because they address the conditions that drive the weight in the first place.

Relevant reading from Meto's clinical team:

• Peptides for Insulin Resistance: GLP-1, Tesamorelin and Emerging Compounds
• Peptide Therapy for PCOS — GLP-1, BPC-157 and Hormonal Peptides

Meto: Insurance-Covered GLP-1 Care With Ongoing Monitoring

If monitoring is your criterion — and it should be — Meto is the only platform in this comparison that meets the full clinical standard while accepting insurance at a typical out-of-pocket cost of $0–$50 per visit.

The process is straightforward:

1. Complete your online health assessment — symptoms, history, and goals reviewed by a clinician
2. Order your lab panel — Meto's pre-GLP-1 metabolic panel covers every required biomarker in a single draw, with results in 3–5 business days
3. Receive a personalised clinical plan — built around your lab results, history, and root-cause diagnosis, not just your BMI
4. Follow your progress with ongoing oversight — biometric tracking, lab review, dose adjustments, and continuous clinical access

This is what a monitored GLP-1 program looks like. Not a questionnaire and a shipment.

Start your Meto assessment today and find out whether GLP-1 therapy is right for you — and what else might need attention first.

Conclusion

The GLP-1 telehealth provider comparison in 2026 ultimately comes down to one question: does the platform monitor you, or does it just prescribe you?

Hims and Henry Meds are fast, low-friction, and minimally monitored. Ro is more flexible but inconsistent on labs. Calibrate and Mochi Health represent genuine steps toward clinical rigour — quarterly monitoring and specialist prescribers, respectively.

Meto operates at a different level. It is the only platform that combines insurance access, required baseline labs, metabolic specialist oversight, ongoing monitoring, and a clinical model that addresses the root causes — not just the symptom on the scale.

A GLP-1 prescription is the beginning of a metabolic conversation, not the end of one. Choose a provider that treats it that way.

Frequently Asked Questions

Which GLP-1 telehealth provider requires labs before prescribing?

Of the major providers, Calibrate, Mochi Health, and Meto require baseline laboratory testing before writing a GLP-1 prescription. Hims and Henry Meds do not require labs at intake. Ro requires them conditionally, based on questionnaire responses. Meto's pre-treatment lab panel is purpose-built for GLP-1 initiation, covering all metabolically relevant biomarkers in a single blood draw.

Is it safe to get semaglutide online without a blood test?

It carries real clinical risk. GLP-1 receptor agonists have absolute contraindications — including active pancreatitis, medullary thyroid carcinoma, and certain kidney disease presentations — that questionnaire-only screening can miss. Undiagnosed diabetes, impaired renal function, and certain drug interactions can only be identified through laboratory testing. The ADA and AACE both recommend baseline metabolic labs before initiating GLP-1 therapy.

How does Meto compare to Hims for GLP-1 treatment?

Hims offers fast access to branded GLP-1 medications (Wegovy, Zepbound) with insurance support, using async-only consultations and no required labs. Meto requires baseline labs, assigns metabolic specialists, accepts insurance with typical $0–$50 copays, and provides ongoing monitoring throughout treatment. Hims is suited for low-risk patients who want a streamlined prescription experience. Meto is suited for patients who want clinical rigour, insurance coverage, and monitoring that matches the standard of care.

What labs should be done before starting a GLP-1?

At minimum: HbA1c, fasting glucose, comprehensive metabolic panel (CMP), eGFR, thyroid stimulating hormone (TSH), lipid panel, and complete blood count (CBC). These biomarkers identify contraindications, establish your clinical baseline, and enable meaningful follow-up monitoring. Meto's metabolic lab panel covers all of these in a single draw.

Does insurance cover GLP-1 telehealth?

Several platforms accept insurance, including Ro, Calibrate, Mochi Health, and Meto. Coverage typically applies to FDA-approved medications like Wegovy (semaglutide) and Zepbound (tirzepatide), not compounded versions. Meto works with most major insurance providers. Average patient out-of-pocket cost per visit is $0–$50. For uninsured patients, Meto also offers transparent self-pay rates.

What is the difference between compounded and branded GLP-1 medications?

Branded GLP-1 medications (Wegovy, Ozempic, Zepbound, Mounjaro) are FDA-approved finished drug products manufactured under strict pharmaceutical standards. Compounded semaglutide and tirzepatide are produced by compounding pharmacies, which are not subject to the same approval process. The FDA has issued enforcement actions against numerous compounding pharmacies and telehealth platforms for substandard practices. Meto's article on research peptides vs pharmaceutical-grade medications covers this distinction in clinical detail.